CFO
PCVX icon

CVA Family Office’s Vaxcyte PCVX Stock Holding History

CVA Family Office’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.28K Buy
+22
New +$1.2K ﹤0.01% 1601
2025
Q3 		– Sell
-15
Closed -$488 – 1333
2025
Q2 		$488 Buy
15
+8
+114% +$262 ﹤0.01% 1241
2025
Q1 		$264 Buy
+7
New +$560 ﹤0.01% 1372

Other funds holding PCVX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

CVA Family Office's PCVX Position: Q2 2026 in Review

CVA Family Office opened a new position in Vaxcyte (PCVX) in Q2 2026: 22 shares worth $1.28K. The stake represents ﹤0.01% of the portfolio and ranks #1601 among its holdings. This is a return to the name: CVA Family Office previously reported a position in PCVX as recently as Q2 2025.

CVA Family Office first reported a position in PCVX in Q1 2025 and has held it in 3 quarters since. 331 funds tracked by Wall St. Rank hold PCVX as of Q2 2026.

  • CVA Family Office held 22 shares of Vaxcyte worth $1.28K as of Q2 2026.
  • Vaxcyte was a new CVA Family Office position in Q2 2026.
  • Vaxcyte made up ﹤0.01% of CVA Family Office's portfolio in Q2 2026, its #1601 holding.
  • CVA Family Office first reported a position in Vaxcyte in Q1 2025 and has held it in 3 quarters since.
  • 331 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2026.

Based on CVA Family Office's 13F filing for Q2 2026, filed 7 Aug 2026.